Agreements reached under this partnership
Business Alliances- 1
Evaluate the potential for anti-Epstein-Barr virus activity
- 2
Obtain experimental evidence supporting its utility as an antiviral therapy for Epstein-Barr virus-associated multiple sclerosis
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
No impact on consolidated results for the fiscal year ending December 2026
| Item | Details |
|---|---|
| Name of alliance partner | National Institute of Neurological Disorders and Stroke (NINDS) |
| Alliance partner's business activities | The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH) |
| Alliance partner's location | United States |
| Type of alliance | Business Alliances |
| Details of the alliance | Evaluate the potential for anti-Epstein-Barr virus activity, Obtain experimental evidence supporting its utility as an antiviral therapy for Epstein-Barr virus-associated multiple sclerosis |
| Contract Period | Extended by three years. The term of this CRADA has been extended through March 2029 |
| Contract Date | March 2023 |
| Alliance start date | March 2023 (start of joint research) |
| Impact on Business Performance | No impact on consolidated results for the fiscal year ending December 2026 |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Multiple sclerosis is a chronic disease, making the development of a more suitable route of administration and formulation important for bringing a treatment to practical use. In addition, based on the research results to date, the agreement will allow the efficacy in humans and the potential for clinical application to be evaluated through clinical trials.